Dhingra Ankur 4/A
4/A · Summit Therapeutics Inc. · Filed Mar 8, 2023
Insider Transaction Report
Form 4/AAmended
Dhingra Ankur
Chief Financial Officer
Transactions
- Purchase
Common Stock
2022-08-16$0.97/sh+13,027$12,636→ 39,527 total - Purchase
Common Stock
2022-08-16$0.97/sh+24,658$23,918→ 38,196 total(indirect: By Trust)
Footnotes (2)
- [F1]This Form 4 is being amended to correct the number of shares purchased by the Reporting Person in the Issuer's rights offering. 1,470 shares were inadvertently omitted from the original filing.
- [F2]The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.